Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics, Incorporated furnished a corporate presentation highlighting the launch of MYQORZO (aficamten), its cardiovascular pipeline and its financial position. The company reported about $1.1 billion in cash, cash equivalents and investments as of March 31, 2026 and described additional access to capital through Royalty Pharma arrangements.
The presentation emphasizes MYQORZO’s FDA approval for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), recent U.S., China and EU launches, and key launch metrics such as REMS-certified prescribers, patient uptake and payer coverage. It also outlines late‑stage programs in non‑obstructive HCM, heart failure with reduced ejection fraction and HFpEF, along with 2026 regulatory and clinical milestones, including an aficamten sNDA PDUFA date of November 14, 2026.
Cytokinetics, Incorporated furnished a corporate presentation highlighting the launch of MYQORZO (aficamten), its cardiovascular pipeline and its financial position. The company reported about $1.1 billion in cash, cash equivalents and investments as of March 31, 2026 and described additional access to capital through Royalty Pharma arrangements.
The presentation emphasizes MYQORZO’s FDA approval for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), recent U.S., China and EU launches, and key launch metrics such as REMS-certified prescribers, patient uptake and payer coverage. It also outlines late‑stage programs in non‑obstructive HCM, heart failure with reduced ejection fraction and HFpEF, along with 2026 regulatory and clinical milestones, including an aficamten sNDA PDUFA date of November 14, 2026.
Cytokinetics, Incorporated furnished a corporate presentation highlighting the launch of MYQORZO (aficamten), its cardiovascular pipeline and its financial position. The company reported about $1.1 billion in cash, cash equivalents and investments as of March 31, 2026 and described additional access to capital through Royalty Pharma arrangements.
The presentation emphasizes MYQORZO’s FDA approval for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), recent U.S., China and EU launches, and key launch metrics such as REMS-certified prescribers, patient uptake and payer coverage. It also outlines late‑stage programs in non‑obstructive HCM, heart failure with reduced ejection fraction and HFpEF, along with 2026 regulatory and clinical milestones, including an aficamten sNDA PDUFA date of November 14, 2026.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.
Cytokinetics reported first quarter 2026 results highlighted by the U.S. launch of MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy. Net product revenue from MYQORZO reached $4.8 million over roughly nine weeks, contributing to total revenues of $19.4 million versus $1.6 million a year earlier.
R&D expenses were $95.5 million and SG&A climbed to $104.9 million, driven by launch spending, leading to a net loss of $206.0 million, or $1.67 per share. The company ended March 31, 2026 with about $1.1 billion in cash, cash equivalents and investments.
Management reported strong early adoption of MYQORZO, with over 275 prescribers and about 680 patients on therapy, and positive Phase 3 ACACIA-HCM data in non-obstructive HCM. MYQORZO also gained European Commission approval, and an FDA supplemental NDA for MAPLE-HCM was accepted with a PDUFA date of November 14, 2026.
Cytokinetics reported first quarter 2026 results highlighted by the U.S. launch of MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy. Net product revenue from MYQORZO reached $4.8 million over roughly nine weeks, contributing to total revenues of $19.4 million versus $1.6 million a year earlier.
R&D expenses were $95.5 million and SG&A climbed to $104.9 million, driven by launch spending, leading to a net loss of $206.0 million, or $1.67 per share. The company ended March 31, 2026 with about $1.1 billion in cash, cash equivalents and investments.
Management reported strong early adoption of MYQORZO, with over 275 prescribers and about 680 patients on therapy, and positive Phase 3 ACACIA-HCM data in non-obstructive HCM. MYQORZO also gained European Commission approval, and an FDA supplemental NDA for MAPLE-HCM was accepted with a PDUFA date of November 14, 2026.
Cytokinetics reported first quarter 2026 results highlighted by the U.S. launch of MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy. Net product revenue from MYQORZO reached $4.8 million over roughly nine weeks, contributing to total revenues of $19.4 million versus $1.6 million a year earlier.
R&D expenses were $95.5 million and SG&A climbed to $104.9 million, driven by launch spending, leading to a net loss of $206.0 million, or $1.67 per share. The company ended March 31, 2026 with about $1.1 billion in cash, cash equivalents and investments.
Management reported strong early adoption of MYQORZO, with over 275 prescribers and about 680 patients on therapy, and positive Phase 3 ACACIA-HCM data in non-obstructive HCM. MYQORZO also gained European Commission approval, and an FDA supplemental NDA for MAPLE-HCM was accepted with a PDUFA date of November 14, 2026.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On May 1, 2026, he exercised a non-qualified stock option covering 15,857 shares of common stock at $37.63 per share and sold 15,857 shares of common stock in an open-market transaction at $65.00 per share.
Following these transactions, Callos directly held 58,555 shares of Cytokinetics common stock. The exercised option had originally been scheduled to vest in equal monthly installments over four years until fully vested.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised options to acquire 15,000 shares of common stock at $23.26 per share and sold 15,000 shares in an open-market transaction at an average price of $63.26 per share.
After these transactions, Callos directly holds 58,555 shares of Cytokinetics common stock and 54,000 non-qualified stock options. The remaining options vest over four years from the grant date, with one quarter vesting after one year and the rest vesting monthly over the following 36 months, subject to continued employment.
Cytokinetics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,422,042 shares of Cytokinetics common stock, constituting 5.21% of the class as of 03/31/2026. The filing lists sole voting power of 933,408 shares and sole dispositive power over all reported shares.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share. The transaction took place on April 29, 2026 and is classified as a non-derivative sale.
After this sale, Blum directly holds 407,830 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised options and sold shares of company stock. He exercised non-qualified stock options for 3,500 shares of Common Stock at $7.80 per share, then completed an open-market sale of 3,500 Common Stock shares at $65.69 per share on the same date. Following these transactions, he directly holds 153,902 shares of Common Stock.